Related references
Note: Only part of the references are listed.Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys
Weirong Wang et al.
AAPS JOURNAL (2014)
Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model
Joanne Brodfuehrer et al.
PHARMACEUTICAL RESEARCH (2014)
Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human β-Nerve Growth Factor
Hendrik Neubert et al.
ANALYTICAL CHEMISTRY (2013)
Utilizing Pharmacokinetics/Pharmacodynamics Modeling to Simultaneously Examine Free CCL2, Total CCL2 and Carlumab (CNTO 888) Concentration Time Data
Gerald J. Fetterly et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Issues, Challenges, and Opportunities in Model-Based Drug Development for Monoclonal Antibodies
Leijun Hu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments
Ryan J. Hansen et al.
MABS (2013)
Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum
Christine Bee et al.
PLOS ONE (2013)
Modeling Alzheimer's disease progression using the disease system analysis approach
Roberto Gomeni et al.
ALZHEIMERS & DEMENTIA (2012)
Novel Method To Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data
Edward P. Acosta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Cumulative disease progression models for cross-sectional data: A review and comparison
Katrin Hainke et al.
BIOMETRICAL JOURNAL (2012)
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
Abhijit Chakraborty et al.
CLINICAL PHARMACOKINETICS (2012)
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Rong Deng et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development
Liang Zhao et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
A novel, high-sensitivity and drug-tolerant sandwich immunoassay for the quantitative measurement of circulating proteins
John H. Sloan et al.
BIOANALYSIS (2012)
Bioanalytical Approaches to Quantify Total and Free Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
Jean W. Lee et al.
AAPS JOURNAL (2011)
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects
Hoai-Thu Thai et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Phase II failures: 2008-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of 'Free' and 'Total' Drug and Target
Cuyue Tang et al.
PHARMACEUTICAL RESEARCH (2011)
On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models
Philip J. Lowe et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
Next-Generation Model-Based Drug Discovery and Development: Quantitative and Systems Pharmacology
S. R. B. Allerheiligen
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand
Hossein Salimi-Moosavi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
Alison M. Betts et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Bart A. Ploeger et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
Leonid Gibiansky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Helen J. Lachmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody
Wendy S. Putnam et al.
AAPS JOURNAL (2008)
Strategic approach to fit-for-purpose biomarkers in drug development
John A. Wagner
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Development of translational pharmacokinetic-pharmacodynamic models
D. E. Mager et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients
Anshu Marathe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
Meindert Danhof et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
Balaji M. Agoram et al.
DRUG DISCOVERY TODAY (2007)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
Jasper J. Haringman et al.
ARTHRITIS AND RHEUMATISM (2006)
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Randall J. Bateman et al.
NATURE MEDICINE (2006)
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
PHARMACEUTICAL RESEARCH (2005)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach
GML Meno-Tetang et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
S Holgate et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene
N Elias et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
